Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

On his Instagram profile, the “Queer Eye” star Jonathan Van Ness detailed that he lost 30 kg with GLP-1 weight-loss ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

At the heart of this discovery lies the role of glucagon-like peptide-1 (GLP-1), a hormone known for its involvement in ...

(HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a ...

When Trova Wine and Market in Dallas shut its doors last month after nearly five years in business, owner Michelle Bonds ...

You know something is a big deal when Big Food gets nervous. The culprit? Popular weight-loss drugs like Ozempic, which mimic the hormone glucagon-like peptide-1 (GLP-1) to curb hunger. But these ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

Terns announced that management will participate in the TD Cowen 45th Annual Healthcare Conference taking place from March 3-5, 2025 in Boston ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...